Literature DB >> 11907466

The promise of microarray technology in melanoma care.

Christina J Kim1, Douglas S Reintgen, Timothy J Yeatman.   

Abstract

BACKGROUND: Genetic aberration is responsible for the development of neoplastic potential in a number of malignancies. These DNA alterations result in significant changes in gene expression that may now be measured and catalogued. The microarray technique screens and identifies expressed genes that may be responsible for tumorigenesis.
METHODS: The authors review the application of the microarray technique in malignant melanoma.
RESULTS: Candidate melanoma suppressor genes have been identified in melanoma cell lines using this technique. Furthermore, molecular classification using gene expression profiling may improve the accuracy of the staging system for determining prognosis.
CONCLUSIONS: The microarray technique is in its initial development for clinical application in a variety of tumor models. Melanoma is an ideal system to study the genetic changes associated with the stepwise progression of malignancy. It may be possible to efficiently screen the entire human genome to identify the particular aberrations in gene expression responsible for tumorigenesis in melanoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907466     DOI: 10.1177/107327480200900107

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  3 in total

1.  Gene expression profiles of giant hairy naevi.

Authors:  M R K Dasu; R E Barrow; H K Hawkins; R L McCauley
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

2.  The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment.

Authors:  Elisabeth A Seftor; P S Meltzer; D A Kirschmann; N V Margaryan; R E B Seftor; Mary J C Hendrix
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

Review 3.  Tissue Microarray: A rapidly evolving diagnostic and research tool.

Authors:  Nazar M T Jawhar
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.